CBT
A rare, little-known minor
Cannabinoid
What is CBT?
CBT (cannabicitran) is a rare minor cannabinoid, formed through a cyclization of other cannabinoids. It's non-intoxicating and appears only in trace amounts in most cannabis.
Effects
Research on CBT is extremely limited, but a few threads exist. A 1984 study found CBT reduced intraocular pressure in rabbits, which put it on the map for glaucoma — the same reason THC was studied decades ago. A 2011 study isolated a compound chemically identical to CBT-C from a rhododendron used in traditional Chinese medicine, where it acted as a histamine inhibitor, hinting at anti-allergic activity. And a 2020 screen of 61 cannabinoids flagged CBT for aromatase inhibition (relevant to estrogen-sensitive breast cancer) — though none of this is established clinical evidence.
Research note
When CBT shows up on a report it's almost always a trace — the practical impact on the experience is negligible. It's a reminder that cannabis contains many more compounds than the famous ones, and that a COA listing an obscure name isn't necessarily meaningful by itself.
Conditions that cite this compound
These condition guides point here — they cover the same compound from the patient side.